D. E. Shaw & Co., Inc. Icosavax, Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.95 - $15.79 $141,104 - $374,459	23,715 New	23,715 $373,000
Q3 2022 Nov 14, 2022	BUY	$3.09 - $9.21 $10,027 - $29,886	3,245 Added 4.59%	74,000 $234,000
Q2 2022 Aug 15, 2022	SELL	$5.7 - $10.33 $105,033 - $190,350	-18,427 Reduced 20.66%	70,755 $405,000
Q1 2022 May 16, 2022	BUY	$4.41 - $22.5 $297,273 - $1.52 Million	67,409 Added 309.6%	89,182 $628,000
Q4 2021 Feb 14, 2022	BUY	$21.07 - $34.98 $47,744 - $79,264	2,266 Added 11.62%	21,773 $498,000
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $484,748 - $785,156	19,507 New	19,507 $577,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.